Etcembly

Etcembly is a biotech company using generative AI to discover and engineer T cell receptor and antibody therapeutics.

The company's platform applies large language models to TCR sequence data to design candidates with high affinity and selectivity for cancer and autoimmune disease targets.

Its lead programme, ETC-101, is a bispecific T cell engager targeting PRAME, a cancer-associated antigen, and was designed entirely using their platform.